What they found
TL;DR (mlx-community/Qwen3.5-35B-A3B-4bit): Lunsotogene parvec is an AAV gene therapy approved in April 2026 to treat profound hearing loss caused by OTOF gene variants by restoring synaptic transmission in inner hair cells. It is indicated for patients with biallelic OTOF mutations who have preserved outer hair cell function and no prior cochlear implant.
Lunsotogene parvec (lunsotogene parvec-cwha; OTARMENI™) is a dual adeno-associated virus (AAV) gene transfer therapy developed by Regeneron Pharmaceuticals for the treatment of profound, congenital hearing loss caused by OTOF variants. Delivery of the OTOF transgene to the inner hair cells facilitates production of functional otoferlin protein to restore synaptic transmission to the auditory nerve. Lunsotogene parvec received its first approval on 23 April 2026 in the USA for the treatment of paediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency > 90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function and no prior cochlear implant in the same ear. This article summarises the milestones in the development of lunsotogene parvec leading to this first approval for OTOF-associated sensorineural hearing loss.
How this applies to our program
While this therapy targets OTOF rather than STRC, it validates the clinical viability of AAV-based gene delivery to restore synaptic function in hair cells, supporting our program’s strategy for DFNB16. The success of restoring auditory nerve transmission in OTOF patients provides a functional benchmark for evaluating potential STRC-targeted interventions.
Key numbers
- Approval date: 23 April 2026
- Hearing loss threshold: >90 dB HL
- Target population: Pediatric and adult patients with biallelic OTOF variants
Links
- pubmed_id: https://pubmed.ncbi.nlm.nih.gov/42547733/
- DOI: https://doi.org/10.1007/s40265-026-02361-7
Connections
[source]auto-indexed 2026-08-05 by strc-lit-watch